AbbVie Inc. Website

AbbVie Inc.

NYSE-ABBV

Basic

  • Market Cap

    $300.89B

  • EV

    $357.22B

  • Shares Out

    1,765.87M

  • Revenue

    $54.4B

  • Employees

    50,000

Margins

  • Gross

    69.17%

  • EBITDA

    48%

  • Operating

    32.11%

  • Pre-Tax

    13.84%

  • Net

    11.02%

  • FCF

    40.24%

Returns (5Yr Avg)

  • ROA

    6.61%

  • ROTA

    -16.36%

  • ROE

    61.24%

  • ROCE

    19.62%

  • ROIC

    17.98%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $183.24

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $18.07B

  • Net Debt

    $56.29B

  • Debt/Equity

    9.24

  • EBIT/Interest

    7.5

Growth (CAGR)

  • Rev 3Yr

    2.72%

  • Rev 5Yr

    10.75%

  • Rev 10Yr

    11.08%

  • Dil EPS 3Yr

    4.87%

  • Dil EPS 5Yr

    -0.87%

  • Dil EPS 10Yr

    2.72%

  • Rev Fwd 2Yr

    3.45%

  • EBITDA Fwd 2Yr

    5.49%

  • EPS Fwd 2Yr

    4.07%

  • EPS LT Growth Est

    7.91%

Dividends

  • Yield

  • Payout

    180.01%

  • DPS

    $6.06

  • DPS Growth 3Yr

    6.9%

  • DPS Growth 5Yr

    8.34%

  • DPS Growth 10Yr

    14.1%

  • DPS Growth Fwd 2Yr

    4.2%

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

LTM

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Total Revenues

33,266

45,804

56,197

58,054

54,318

54,403

Total Revenues % Chg.

1.6%

37.7%

22.7%

3.3%

-6.4%

-4.1%

Cost of Goods Sold, Total

7,439

15,257

17,314

16,527

16,726

16,770

Gross Profit

25,827

30,547

38,883

41,527

37,592

37,633

Selling General & Admin Expenses, Total

6,763

9,867

11,872

12,084

12,904

12,973

R&D Expenses

5,377

6,003

6,820

6,487

7,038

7,189

Other Operating Expenses

-560

432

-1

-10

Other Operating Expenses, Total

11,580

15,870

19,124

18,570

19,932

20,162

Operating Income

14,247

14,677

19,759

22,957

17,660

17,471

Interest Expense, Total

-1,784

-2,454

-2,423

-2,230

-2,224

-2,331

Interest And Investment Income

275

174

39

186

540

648

Net Interest Expenses

-1,509

-2,280

-2,384

-2,044

-1,684

-1,683

Currency Exchange Gains (Loss)

-42

-71

-51

-148

-146

-115

Other Non Operating Income (Expenses)

9

113

55

142

190

196

EBT, Excl. Unusual Items

12,705

12,439

17,379

20,907

16,020

15,869

Restructuring Charges

Merger & Related Restructuring Charges

-103

-1,912

-587

-768

-119

-516

Gain (Loss) On Sale Of Investments

Gain (Loss) On Sale Of Assets

330

172

Asset Writedown

-1,030

-876

-4,230

-3,600

In Process R&D Expenses

-385

-1,376

-1,124

-697

-778

-792

Legal Settlements

-2,500

485

485

Other Unusual Items

-3,091

-5,753

-2,679

-2,761

-5,128

-3,916

EBT, Incl. Unusual Items

8,426

3,398

12,989

13,477

6,250

7,530

Income Tax Expense

544

-1,224

1,440

1,632

1,377

1,526

Earnings From Continuing Operations

7,882

4,622

11,549

11,845

4,873

6,004

Minority Interest

-6

-7

-9

-10

-11

Net Income

7,882

4,616

11,542

11,836

4,863

5,993

Preferred Dividend and Other Adjustments

40

60

74

54

43

42

Net Income to Common Incl Extra Items

7,842

4,556

11,468

11,782

4,820

5,951

Net Income to Common Excl. Extra Items

7,842

4,556

11,468

11,782

4,820

5,951

Total Shares Outstanding

1,478.9

1,765.1

1,768.3

1,769.2

1,765.9

1,765.7

Weighted Avg. Shares Outstanding

1,481

1,667

1,770

1,771

1,768

1,767.8

Weighted Avg. Shares Outstanding Dil

1,484

1,673

1,777

1,778

1,773

1,772.3

EPS

5.3

2.7

6.5

6.7

2.7

3.4

EPS Diluted

5.3

2.7

6.5

6.6

2.7

3.4

EBITDA

16,264

21,148

28,280

31,424

26,358

26,116

Effective Tax Rate

6.5%

-36%

11.1%

12.1%

22%

20.3%